Sunshine Biopharma (SBFM) Total Current Liabilities (2015 - 2026)

Sunshine Biopharma's Total Current Liabilities history runs 12 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• Quarterly Total Current Liabilities rose 2.01% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 2.01% YoY) and the FY2025 annual result came in at $6.4 million, up 2.04% from the prior year.
• Total Current Liabilities was $5.9 million for Q1 2026 at Sunshine Biopharma, down from $6.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $6.9 million in Q4 2022 and bottomed at $95234.0 in Q1 2022.
• A 5-year average of $4.9 million and a median of $5.6 million in 2025 frame the typical range for Total Current Liabilities.
• Peak annual rise in Total Current Liabilities reached 7497.38% in 2022, while the deepest fall reached 88.99% in 2022.
• Sunshine Biopharma's Total Current Liabilities stood at $6.9 million in 2022, then retreated by 19.9% to $5.6 million in 2023, then climbed by 13.74% to $6.3 million in 2024, then climbed by 2.04% to $6.4 million in 2025, then decreased by 8.78% to $5.9 million in 2026.
• Business Quant data shows SBFM's Total Current Liabilities at $5.9 million in Q1 2026, $6.4 million in Q4 2025, and $6.7 million in Q3 2025.